Latest Osteoporosis Stories

Provinical Governments List Aclasta on Public Drug Plans TORONTO, Nov. 22, 2012 /CNW/ - Osteoporosis Canada congratulates the Ontario government, the New Brunswick government, the Saskatchewan government and the British Columbia government for providing access to a new osteoporosis medication. Aclasta (zoledronic acid) is now available on public and private drug plans in Ontario, BC, SK, and NB meaning Canadians at high risk for fractures have access to increased treatment...

Expert Panel Confirms Safety of Calcium Supplements in Relation to Cardiovascular Disease Individuals who do not obtain recommended intake levels of calcium through dietary sources can safely utilize calcium supplements to achieve optimal bone health, an expert panel concludes. These findings appear in the November online edition of Advances in Nutrition, a journal that highlights the significance of recent research in nutrition and illustrates the central role of nutrition in the...

Lee Rannals for redOrbit.com – Your Universe Online A new study conducted by European researchers analyzed the health economics of increased dairy food, showing the benefits of boosting dietary calcium intake. The latest research reported in the journal Osteoporosis International shows that increasing consumption of dairy foods helps to prevent hip fractures and reduce healthcare costs. The study was based on a new analytical model that links nutrition and fracture risk, and...

Patients treated with an epidural steroid injection for back pain relief are at increased risk of bone fractures in the spine, according to a Henry Ford Hospital study. Researchers say the risk of fracture increased 29 percent with each steroid injection, a finding they believe raises patient safety concerns. "For a patient population already at risk for bone fractures, steroid injections carry a greater risk that previously thought and actually pose a hazard to the bone," says Shlomo...

Estate of Fosamax User Who Developed Osteonecrosis of the Jaw Reaches Confidential “Stipulation Agreement” with Merck on Damages. Melville, NY (PRWEB) October 25, 2012 The Fosamax side effect lawyers at Alonso Krangle LLP, a national law firm focused on fighting for the rights of serious personal injury victims, reports that Merck & Co. has reached a confidential “stipulation agreement” with the estate of a Fosamax user who developed Osteonecrosis of the Jaw (ONJ), or Dead Jaw...

FREIENBACH, Switzerland, October 23, 2012 /PRNewswire/ -- EffRx to Regain Rights Outside of North America EffRx Pharmaceuticals SA [http://www.effrx.com ] is proud to announce that BINOSTO(TM) [http://www.binosto.com ](alendronate sodium) Effervescent Tablet for buffered oral solution (70 mg) is now available by prescription in the United States. The U.S. Food and Drug Administration earlier this year approved BINOSTO [http://www.binosto.com ]to...

Statin use is associated with protection from esophagus cancer according to a new meta-analysis of existing clinical studies exploring the cancer prevention effects of statins presented by a Mayo Clinic researcher, Dr. Siddharth Singh, at the American College of Gastroenterology 77th Annual Scientific Meeting in Las Vegas, NV. Dr. Singh and his Mayo colleagues conducted a systematic review of eleven studies reporting 8,613 cases of esophageal cancer from studies including almost 1 million...

NYON, Switzerland, October 22, 2012 /PRNewswire/ -- "A wrist fracture is a warning sign," says Professor John A. Kanis, president of the International Osteoporosis Foundation (IOF). "We urge all adults aged 50 and over who have suffered a wrist or other fragility fracture, to get tested for osteoporosis." Osteoporosis is a chronic 'silent' disease that causes bones to weaken and become more fragile and breakable. At age 50, up to one in two women and one in five men...

BOONTON, N.J., Oct. 16, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that its licensee, Tarsa Therapeutics, reported that a Phase 2 trial of its oral recombinant salmon calcitonin in the prevention of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, clinically relevant improvements in bone mineral density...

MINNEAPOLIS and PHILADELPHIA, Oct. 16, 2012 /PRNewswire/ -- Tarsa Therapeutics, Inc. today announced that a Phase II trial of its oral recombinant salmon calcitonin in the prevention of postmenopausal osteoporosis was successfully concluded and yielded statistically significant, clinically relevant improvements in bone mineral density (BMD) at the lumbar spine. These data were presented at the American Society for Bone and Mineral Research (ASBMR) 2012 Annual Meeting by Phase II...